Developer docs
API playgroundTry for free, no card

Search company profiles

StemGenex

Full company profile

uuid0008gaa

Namestring
StemGenex
Legal namestring
Not available - no legal name found in source content for StemGenex
Websiteurl
stemgenex.com
Company typeenum
Private
Founded yearint
2007
Descriptiontext

StemGenex is a private for-profit stem cell therapy provider headquartered in San Diego, California, founded in 2007. The company describes its mission as providing patient access to stem cell therapy for individuals suffering from inflammatory and degenerative illnesses. It operates as a clinical services organization with 11-50 employees, indicating a small-scale practice rather than a multi-site healthcare system. Rita Alexander serves as Founder and Chief Administrative Officer, consistent with a founder-led operating model that has been in place since inception.

The company's core offering centers on administering stem cell-based treatments, though specific treatment protocols, cell types processed, regulatory pathways (e.g., autologous vs. allogeneic, FDA 361 HCT/P vs. IND-regulated biologics), and clinical indications are not disclosed in the available data. No proprietary technology platforms, patents, or scientific publications are referenced, and the technology footprint appears limited to standard clinical operations rather than a technology-driven business model.

Business model details are not disclosed in available data, but the positioning as a direct-access stem cell therapy provider implies patient-pay clinical services revenue, typical of cash-pay regenerative medicine clinics in the U.S. market. No pricing structure, patient volume figures, payer relationships, partnerships, or revenue disclosures are available. The input corpus is dominated by unrelated third-party content (a Dutch online casino review website), which provides no material company information.

Short descriptiontext

StemGenex is a private San Diego-based stem cell therapy clinic founded in 2007 that provides patient access to regenerative cell-based treatments for individuals with inflammatory and degenerative illnesses, operating with 11-50 employees.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
stem cell therapy, regenerative medicine, adult stem cells, cell therapy treatments, inflammatory disease therapy
Industry4 codes
1Stem Cell Therapies (MSC/iPSC/HSC-derived)
CodeHLAAABAEPrimaryYes
2Stem Cell–Based Regenerative Therapies
CodeHLAAAGAAPrimaryNo
3Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics)
CodeHLAAAGALPrimaryNo
4Cell Therapy Developers (Autologous)
CodeHLAAABAAPrimaryNo
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Health Services8000
Product category
Regenerative Medicine
Social media profiles1 record
Cost components4 values
Personnel, Operations, Marketing or Sales, Technology or R&D
GTM typeB2C
B2C
Offering typeServices
Services
Core offering1 text field

StemGenex is dedicated to providing access to adult stem cell therapy for individuals suffering with inflammatory and degenerative illnesses. The company delivers autologous (patient-derived) stem cell treatments at its San Diego clinical site, processing and re-administering patients' own stem cells as a regenerative therapy.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Adult Stem Cell Therapy
CategoryRegenerative Medicine / Cell Therapy
Description

Stem cell therapy service in which adult stem cells (derived from the patient's own tissue) are processed and re-administered to treat inflammatory and degenerative illnesses. The service is offered to individual patients at StemGenex's San Diego clinical site.

Recent move1 record

Each record includes

Date, Type, Title, Description, Source

Expansion highlight1 record

Each record includes

Type, Description

Peers8 records
1NSI Stem Cell
TypeDirect peer
Description

NSI Stem Cell operates a national US clinic network providing autologous stem cell therapies for musculoskeletal and systemic conditions. Highly comparable to StemGenex in clinic model, indications served, and direct-to-patient marketing approach.

2Celltex Therapeutics
TypeDirect peer
Description

Celltex Therapeutics is a Houston-based stem cell therapy company offering autologous mesenchymal stem cell banking and treatments. It overlaps with StemGenex on cell source (autologous MSC), regenerative medicine indications, and US clinic-based delivery model.

3AgeX Therapeutics
TypeBroad incumbent
Description

AgeX Therapeutics is a US-based biotechnology company focused on regenerative medicine and cellular therapies for age-related degenerative diseases. It is a broader incumbent operating earlier in the value chain (R&D rather than clinic delivery), but addresses the same underlying indication categories as StemGenex.

4Mesoblast
TypeBroad incumbent
Description

Mesoblast is an Australian-listed clinical-stage biotechnology company developing allogeneic cellular medicines for inflammatory and degenerative diseases. It is a broader incumbent addressing overlapping indications (e.g., degenerative disc disease, heart failure) but delivers via pharmaceutical rather than clinic channels.

5BioXcellerator
TypeDirect peer
Description

BioXcellerator operates stem cell clinics treating inflammatory, autoimmune, and degenerative conditions using bone marrow and adipose-derived stem cells. Comparable to StemGenex in therapeutic focus, autologous sourcing, and premium cash-pay clinic delivery model.

6Regenexx
TypeDirect peer
Description

Regenexx is a US-based network of clinics offering autologous stem cell and platelet-rich plasma treatments for orthopedic and inflammatory conditions. It is the most directly comparable peer to StemGenex in terms of service model, target indications, and direct-to-consumer cash-pay approach.

7The Lung Institute
TypeDirect peer
Description

The Lung Institute is a US-based regenerative medicine clinic specializing in stem cell therapy for chronic pulmonary and inflammatory conditions. Comparable to StemGenex in clinic-based, direct-to-consumer stem cell service delivery.

8GIOSTAR
TypeDirect peer
Description

GIOSTAR is a regenerative medicine clinic group offering stem cell therapies for inflammatory and degenerative diseases with locations in the US and internationally. It is comparable to StemGenex across indication focus, autologous stem cell delivery, and consumer-targeted positioning.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

StemGenex

Regenerative Medicinestemgenex.com

StemGenex is a private San Diego-based stem cell therapy clinic founded in 2007 that provides patient access to regenerative cell-based treatments for individuals with inflammatory and degenerative illnesses, operating with 11-50 employees.

What StemGenex does

StemGenex is a private for-profit stem cell therapy provider headquartered in San Diego, California, founded in 2007. The company describes its mission as providing patient access to stem cell therapy for individuals suffering from inflammatory and degenerative illnesses. It operates as a clinical services organization with 11-50 employees, indicating a small-scale practice rather than a multi-site healthcare system. Rita Alexander serves as Founder and Chief Administrative Officer, consistent with a founder-led operating model that has been in place since inception.

The company's core offering centers on administering stem cell-based treatments, though specific treatment protocols, cell types processed, regulatory pathways (e.g., autologous vs. allogeneic, FDA 361 HCT/P vs. IND-regulated biologics), and clinical indications are not disclosed in the available data. No proprietary technology platforms, patents, or scientific publications are referenced, and the technology footprint appears limited to standard clinical operations rather than a technology-driven business model.

Business model details are not disclosed in available data, but the positioning as a direct-access stem cell therapy provider implies patient-pay clinical services revenue, typical of cash-pay regenerative medicine clinics in the U.S. market. No pricing structure, patient volume figures, payer relationships, partnerships, or revenue disclosures are available. The input corpus is dominated by unrelated third-party content (a Dutch online casino review website), which provides no material company information.

StemGenex firmographics

Firmographics
Name
StemGenex
Legal name
Not available - no legal name found in source content for StemGenex
Website
https://stemgenex.com
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
11–50 employees
Short description
StemGenex is a private San Diego-based stem cell therapy clinic founded in 2007 that provides patient access to regenerative cell-based treatments for individuals with inflammatory and degenerative illnesses, operating with 11-50 employees.
Ownership category
akta.pro rank

StemGenex industry classification

Industry
Product category
Regenerative Medicine
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Health Services (8000)
akta.pro primary industry
Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)
akta.pro secondary industries
Stem Cell–Based Regenerative Therapies (HLAAAGAA), Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics) (HLAAAGAL), Cell Therapy Developers (Autologous) (HLAAABAA)

Keywords

  • Stem cell therapy
  • Regenerative medicine
  • Adult stem cells
  • Cell therapy treatments
  • Inflammatory disease therapy

Where StemGenex is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Markets served

StemGenex business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D

StemGenex product offering

Product offering

Core offering

StemGenex is dedicated to providing access to adult stem cell therapy for individuals suffering with inflammatory and degenerative illnesses. The company delivers autologous (patient-derived) stem cell treatments at its San Diego clinical site, processing and re-administering patients' own stem cells as a regenerative therapy.

Differentiator

Problem solved

Functional benefit

Products and services

  • Adult Stem Cell Therapy Stem cell therapy service in which adult stem cells (derived from the patient's own tissue) are processed and re-administered to treat inflammatory and degenerative illnesses. The service is offered to individual patients at StemGenex's San Diego clinical site.

Companies that use StemGenex

Customer profile

Ideal customer profiles1 record

StemGenex technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

StemGenex partnerships and signals

Strategic signal

Recent moves1 record

Expansion highlights1 record

StemGenex competitors and assessment

Company assessment

Direct peers

  • NSI Stem Cell: NSI Stem Cell operates a national US clinic network providing autologous stem cell therapies for musculoskeletal and systemic conditions. Highly comparable to StemGenex in clinic model, indications served, and direct-to-patient marketing approach.
  • Celltex Therapeutics: Celltex Therapeutics is a Houston-based stem cell therapy company offering autologous mesenchymal stem cell banking and treatments. It overlaps with StemGenex on cell source (autologous MSC), regenerative medicine indications, and US clinic-based delivery model.
  • BioXcellerator: BioXcellerator operates stem cell clinics treating inflammatory, autoimmune, and degenerative conditions using bone marrow and adipose-derived stem cells. Comparable to StemGenex in therapeutic focus, autologous sourcing, and premium cash-pay clinic delivery model.
  • Regenexx: Regenexx is a US-based network of clinics offering autologous stem cell and platelet-rich plasma treatments for orthopedic and inflammatory conditions. It is the most directly comparable peer to StemGenex in terms of service model, target indications, and direct-to-consumer cash-pay approach.
  • The Lung Institute: The Lung Institute is a US-based regenerative medicine clinic specializing in stem cell therapy for chronic pulmonary and inflammatory conditions. Comparable to StemGenex in clinic-based, direct-to-consumer stem cell service delivery.
  • GIOSTAR: GIOSTAR is a regenerative medicine clinic group offering stem cell therapies for inflammatory and degenerative diseases with locations in the US and internationally. It is comparable to StemGenex across indication focus, autologous stem cell delivery, and consumer-targeted positioning.

Broad incumbents

  • AgeX Therapeutics: AgeX Therapeutics is a US-based biotechnology company focused on regenerative medicine and cellular therapies for age-related degenerative diseases. It is a broader incumbent operating earlier in the value chain (R&D rather than clinic delivery), but addresses the same underlying indication categories as StemGenex.
  • Mesoblast: Mesoblast is an Australian-listed clinical-stage biotechnology company developing allogeneic cellular medicines for inflammatory and degenerative diseases. It is a broader incumbent addressing overlapping indications (e.g., degenerative disc disease, heart failure) but delivers via pharmaceutical rather than clinic channels.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

StemGenex social profiles

Digital presence

StemGenex financial estimates

Financial estimate

Revenue estimate

Valuation estimate

StemGenex leadership team

Management profile

Number of profiles

Profiles1 record

StemGenex funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

StemGenex M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about StemGenex

What does StemGenex do?

StemGenex is dedicated to providing access to adult stem cell therapy for individuals suffering with inflammatory and degenerative illnesses. The company delivers autologous (patient-derived) stem cell treatments at its San Diego clinical site, processing and re-administering patients' own stem cells as a regenerative therapy.

When was StemGenex founded?

StemGenex was founded in 2007. It employs 11 to 50 people.

Where is StemGenex based?

StemGenex is headquartered in San Diego, United States, in the North America region.

Who are StemGenex's main competitors?

Direct peers on record are NSI Stem Cell, Celltex Therapeutics, BioXcellerator, Regenexx, The Lung Institute and GIOSTAR. Broad incumbents are AgeX Therapeutics and Mesoblast.

Does StemGenex have an API?

No public API is recorded for StemGenex.

What industry is StemGenex in?

StemGenex's product category is Regenerative Medicine. Its primary akta.pro industry code is HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived), with a secondary code of HLAAAGAA, Stem Cell–Based Regenerative Therapies. Its NAICS code is 541714 and its SIC code is 8000.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireFDA warns StemGenex Biologic Laboratories LLC of illegally marketing an unapproved cellular product manufactured in a facility with significant manufacturing violations, putting patients at riskThe U.S. Food and Drug Administration issued a warning letter to StemGenex Biologic Laboratories LLC for marketing an unapproved stem cell product and violating current good manufacturing practices. The agency cited significant risks of microbial contamination due to unvalidated processes and uncontrolled environments at the San Diego facility. The FDA has demanded a corrective action plan within 15 working days or faces potential enforcement actions such as seizure or prosecution.PR NewswirePatient-Centered Stem Cell Therapy Bill Passed by Texas LegislatureThe Texas legislature has passed House Bill 810, a 'Right to Try' law that will allow patients with incurable illnesses to access stem cell therapies not yet approved by the FDA upon the Governor's signature. StemGenex Medical Group, a provider of such treatments, applauded the legislation as it aligns with similar advocacy efforts in other states to remove regulatory obstacles for terminally ill patients.PR NewswireStemGenex Applauds Kelly Osbourne for Supporting Stem Cell TherapyStemGenex Medical Group publicly praised Kelly Osbourne for her advocacy of stem cell therapy after she disclosed her struggle with Lyme disease, which was misdiagnosed as epilepsy before she sought treatment in Frankfurt, Germany. The company highlighted its use of adipose-derived stem cells for autoimmune and degenerative conditions such as Multiple Sclerosis, Parkinson's disease, and Rheumatoid Arthritis, noting five clinical outcome studies registered with the NIH. The article also referenced the 21st Century Cures Act signed by President Obama in 2016, which provided the FDA with flexibility to accelerate evaluation of regenerative medicine treatments.PR NewswireStemGenex Recognizes Parkinson's Awareness MonthStemGenex Medical Group, a California-based stem cell therapy provider, recognized Parkinson's Awareness Month in April 2017 by highlighting its treatment program for the disease, which is the second most treated condition at its AAAHC Accredited Surgical Center. The organization sponsors the annual Birdies Fore Parkinson's Research golf tournament, with proceeds donated to the Michael J. Fox Foundation, and promotes its stem cell therapy as an alternative for patients who do not respond to traditional medication. The article also references the 21st Century Cures Act signed in December 2016, which provides the FDA flexibility to accelerate evaluation of regenerative medicine treatments such as stem cell therapies.PR NewswireCourt Rules in Favor of StemGenex on Majority of Allegations in Proposed Class Action LawsuitThe United States District Court for the Southern District of California ruled largely in favor of StemGenex Medical Group in a proposed class action lawsuit, dismissing the bulk of plaintiff's allegations including false-advertising claims based on lack of substantiation, fraud, negligent misrepresentation, human experimentation, financial elder abuse, and RICO claims. The court found that false-advertising claims require provable falsehood rather than mere lack of substantiation under California consumer-protection laws, and that stem cell treatments are 'reasonably related' to maintaining or improving health rather than constituting 'pure research.' StemGenex expressed optimism about being completely exonerated on the remaining issues while acknowledging some elements of the case were upheld.PR NewswireStemGenex Steps Up to Support Walk MSStemGenex Medical Group has become a Diamond Sponsor for the Walk MS events in San Diego and Carlsbad, with proceeds supporting the National Multiple Sclerosis Society. In addition to financial sponsorship, StemGenex will donate tricycles for each event to assist participants.PR NewswireStemGenex Supports Rheumatoid Arthritis Awareness DayStemGenex Medical Group marked Rheumatoid Arthritis Awareness Day on February 2, 2017, promoting stem cell therapy as a treatment option for the estimated one-third of RA patients who do not respond to standard medications. The company cited the 21st Century Cures Act signed into law in December 2016 as landmark legislation designed to accelerate FDA approval processes for new medical treatments including stem cell therapies. StemGenex sponsors five clinical outcome studies registered with the National Institutes of Health for conditions including Rheumatoid Arthritis.PR NewswireLandmark Bill Helps Regulation Catch Up to 21st Century Stem Cell TherapiesPresident Obama signed the 21st Century Cures Act into law on December 19, 2016, landmark legislation designed to accelerate FDA evaluation of regenerative medicine treatments including stem cell therapies. The law directs the FDA to consider real-world evidence such as patient registries and electronic health records alongside formal clinical trial data in risk-benefit assessments. StemGenex, a stem cell therapy provider, actively advocated for the legislation by presenting at an FDA public hearing and having patients testify in Washington, D.C. about their treatment experiences.PR NewswireStemGenex Comments on FDA Docket to Support Stem Cell TherapyStemGenex Medical Group submitted comments to the FDA docket opposing the proposed regulation of adult adipose-derived stem cell treatments as manufactured drugs, arguing it would delay patient access and require 10-15 years and tens of millions of dollars for approval. The company instead proposed that stem cell therapies be regulated under existing accrediting organizations like the American Association of Blood Banks (AABB), citing their established 20-year track record of setting safety standards for blood and tissue products. StemGenex also advocated for a National Directory requiring stem cell treatment providers and clinics to register as an alternative regulatory pathway.PR NewswireStemGenex Presents at FDA Hearing in Washington, D.C.StemGenex's Chief Scientific Officer Dr. Steven Brody presented at an FDA public hearing on September 12-13, 2016, in Bethesda, MD, advocating for regulatory changes to how adult stem cell therapies derived from adipose tissue are governed. The hearing drew nearly 500 attendees and 90 speakers to comment on four draft guidances related to the regulation of human cells, tissues, and cellular-based products. StemGenex called on the FDA to expand the definition of minimal manipulation and to regulate stem cell products under existing standards similar to those used by organizations like the American Association of Blood Banks (AABB), arguing this would accelerate patient access to therapies for unmet clinical needs.